Flexion Therapeuticsincis A Biopharmaceutical Company Based In Burlingtonmafocused On Developing Localized Therapies For Musculoskeletal Conditionsespecially Osteoarthritisoa The Company Aims To Meet The Needs In Pain Management With Non Opioid Treatments That Minimize Systemic Side Effects Associated With Oral Medicationsflexion Engages In The Discoverydevelopmentand Commercialization Of Innovative Therapiesemphasizing Intra Articular Injections And Gene Therapy To Directly Target Pain And Inflammationits Key Productzilrettaa Is An Fda Approved Injection For Managing Oa Knee Painproviding Relief For Up To 12 Weeksthe Company Is Also Advancing Fx201A Clinical Phase Gene Therapy Aimed At Modifying Oa Progressionand Fx301An Investigational Treatment For Post Operative Painflexion Serves Patients With Osteoarthritis And Healthcare Providers Seeking Effectivelocalized Treatment Options
